NewAmsterdam Pharma (NAMS) Liabilities and Shareholders Equity (2021 - 2026)

NewAmsterdam Pharma has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $732.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 10.48% year-over-year to $732.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 20.81% YoY) and the FY2025 annual result came in at $769.3 million, down 11.03% from the prior year.
• Liabilities and Shareholders Equity declined to $732.6 million in Q1 2026 per NAMS's latest filing, from $769.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $864.6 million in Q4 2024 and troughed at $347.1 million in Q4 2023.
• A 5-year average of $630.3 million and a median of $637.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity jumped 693.03% in 2022, then slumped 36.0% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $542.3 million in 2022, then plunged by 36.0% to $347.1 million in 2023, then surged by 149.1% to $864.6 million in 2024, then decreased by 11.03% to $769.3 million in 2025, then declined by 4.76% to $732.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $732.6 million, $769.3 million, and $786.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.